Groundbreaking Market Report Forecasts Significant Growth in Cancer Immunotherapy by 2027
19 sept. 2024 09h41 HE
|
Research and Markets
Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer...
ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
17 sept. 2024 04h00 HE
|
AKAMPION
Existing investors and new investor Double Point Ventures join forces to support ImmunOs TherapeuticsInvestment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers ...
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
16 sept. 2024 05h25 HE
|
https://immatics.com/
TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8 with high target copy numbers on...
BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC
12 sept. 2024 16h56 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its...
Le PIONeeR Project présentera pour la première fois les résultats de son étude clinique de phase Ib/IIa lors de l’ESMO 2024
12 sept. 2024 04h21 HE
|
The PIONeeR Project
Le PIONeeR Project présentera pour la première fois les résultats de son étude clinique de phase Ib/IIa lors de l’ESMO 2024 Le symposium présidentiel "Eyes to the future" sera l'occasion de présenter...
The PIONeeR Project to Present Late-Breaking Results from its Phase Ib/IIa umbrella study at the ESMO Congress 2024
12 sept. 2024 04h21 HE
|
The PIONeeR Project
The PIONeeR Project to Present Late-Breaking Results from its Phase Ib/IIa umbrella study at the ESMO Congress 2024 The Presidential Symposium "Eyes to the future" will feature the first-ever...
CD137 Antibodies Clinical Trials & Market Opportunity - Revolutionary CD137 Antibodies Poised to Transform Cancer Immunotherapy Landscape by 2027
12 sept. 2024 04h01 HE
|
Research and Markets
Dublin, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The "CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027" report has been added to ResearchAndMarkets.com's offering. CD137, also...
Gastric Cancer Market Research Report 2024-2030 by Immunotherapy, Chemotherapy, Radiation Therapy, Surgery, Target Therapies, PD-1/PD-L1 Inhibitors, HER2 Antagonists VEGFR2 Antagonists
11 sept. 2024 11h03 HE
|
Research and Markets
Dublin, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The "Global Gastric Cancer Market (2024 Edition): Analysis By Indication (Gastric Cancer/Gastroesophageal Junction Cancer, Gastrointestinal Stromal...
Testicular Cancer Drugs Market Forecast Report 2024-2030 - Focus on Reducing Treatment Toxicity Enhances Demand for Novel Testicular Cancer Drugs
09 sept. 2024 11h20 HE
|
Research and Markets
Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "Testicular Cancer Drugs - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Testicular...
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
06 sept. 2024 07h00 HE
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and...